Selective estrogen receptor modulator and selective progesterone receptor modulator: Therapeutic efficacy in the treatment of uterine leiomyoma

Clinical and Experimental Obstetrics and Gynecology

Volumn 32, Issue 1, 2005, Pages 9-11

  Ohara, N ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Leiomyoma; Selective estrogen receptor modulator (SERM); Selective progesterone receptor modulator (SPRM)

Indexed keywords

ANTIGESTAGEN; ASOPRISNIL; GONADORELIN AGONIST; MIFEPRISTONE; PROGESTERONE RECEPTOR MODULATOR; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; UNCLASSIFIED DRUG;

DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRY SKIN; ENDOMETRIUM HYPERPLASIA; FEMALE; HOT FLUSH; HUMAN; LEG CRAMP; LIVER TOXICITY; LUNG EMBOLISM; MONOTHERAPY; NAUSEA; POSTMENOPAUSE; PREMENOPAUSE; REVIEW; SIDE EFFECT; STOMACH PAIN; SYMPTOMATOLOGY; THROMBOEMBOLISM; TREATMENT OUTCOME; TUMOR GROWTH; TUMOR VOLUME; UTERUS MYOMA;

FEMALE; FERTILITY AGENTS, FEMALE; GONADOTROPIN-RELEASING HORMONE; HORMONE ANTAGONISTS; HUMANS; LEIOMYOMA; RECEPTORS, PROGESTERONE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; UTERINE NEOPLASMS;

EID: 17444377968     PISSN: 03906663     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (21)

1. Maruo T., Ohara N., Wang J., Matsuo H.: "Sex steroidal regulation of uterine leiomyoma growth and apoptosis". Hum. Reprod. Update, 2004, 10, 207.
2. Morello K.C., Wunz G.T., DeGregorio M.W.: "SERMs: current status and future trends". Crit. Rev. Oncol. Hematol, 2002, 43, 63.
3. Spitz I.M.: "Progesterone antagonists and progesterone receptor modulators: an overview". Steroids, 2003, 68, 981.
4. Howe S.R., Gottardis M.M., Everitt J.I., Walker C.: "Estrogen stimulation and tamoxifen inhibition of leiomyoma cell growth in vitro and in vivo". Endocrinology, 1995, 136, 4996.
5. Fuchs-Young R., Howe S., Hale L., Miles R., Walker C.: "Inhibition of estrogen-stimulated growth of uterine leiomyomas by selective estrogen receptor modulators". Mol. Carcinog., 1996, 17, 151.
6. Porter K.B., Tsibris J.C.M., Porter G.W., Fuchs-Young R., Nicosia S.V., O'Brien W.F. et al.: "Effects of raloxifene in a guinea pig model for leiomyomas". Am. J. Obstet. Gynecol., 1998, 179, 1283.
7. Walker C.L., Burroughs K.D., Davis B., Sowell K., Everitt J.I., Fuchs-Young R.: "Preclinical evidence for therapeutic efficacy of selective estrogen receptor modulators for uterine leiomyoma". J. Soc. Gynecol. Investig., 2000, 7, 249.
8. Sadan O., Ginath S., Sofer D., Rotmensch S., Debby A., Glezerman M. et al.: "The role of tamoxifen in the treatment of symptomatic uterine leiomyomata - a pilot study". Eur. J. Obstet. Gynecol. Reprod. Biol., 2001, 96, 183.
9. Palomba S., Sammartino A., Di Carlo C., Affinito P., Zullo F., Nappi C.: "Effects of raloxifene treatment on uterine leiomyomas in postmenopausal women". Fertil. Steril., 2001, 76, 38.
10. Palomba S., Orio F. Jr., Morelli M., Russo T., Pellicano M., Zupi E. et al.: "Raloxifene administration in premenopausal women with uterine leiomyomas: a pilot study". J. Clin. Endocrinol. Metab., 2002, 87, 3603.
11. Jirecek S., Lee A., Pavo I., Crans G., Eppel W., Werzl R.: "Raloxifene prevents the growth of uterine leiomyomas in premenopausal women". Fertil. Steril., 2004, 81, 132.
12. Palomba S., Zullo F.: "Does raloxifene inhibit the growth of uterine fibroids?". Fertil. Steril., 2004, 81, 1719.
13. Donnez J., Vivancos B.H., Kudela M., Audebert A., Jadoul P.: "A randomized, placebo-controlled, dose-ranging trial comparing fulvestrant with goserelin in premenopausal patients with uterine fibroids awaiting hysterectomy". Fertil. Steril., 2003, 79, 1380.
14. Palomba S., Russo T., Orio F. Jr., Tauchmanova L., Zupi E., Panici P.L.B. et al.: "Effectiveness of combined GnRH analogue plus raloxifene administration in the treatment of uterine leiomyomas: a prospective, randomized, single-blind, placebo-controlled clinical trial". Hum. Reprod., 2002, 17, 3213.
15. Palomba S., Orio F. Jr., Morelli M., Russo T., Pellicano M., Nappi C. et al.: "Raloxifene administration in women treated with gonadotropin- releasing hormone agonist for uterine leiomyomas: effects on bone metabolism". J. Clin. Endocrinol. Metab., 2002, 87, 4476.
16. Palomba S., Orio F. Jr., Russo T., Falbo A., Cascella T., Doldo P. et al.: "Long-term effectiveness and safety of GnRH agonist plus raloxifene administration in women with uterine leiomyomas". Hum. Reprod., 2004, 19, 1308.
17. Murphy A.A., Kettel L.M., Morales A.J., Roberts V.J., Yen S.S.C.: "Regression of uterine leiomyomata in response to the antiprogesterone RU486". J. Clin. Endocrinol. Metab., 1993, 76, 513.
18. Murphy A.A., Morales A.J., Kettel L.M., Yen S.S.C.: "Regression of uterine leiomyomata to the antiprogesterone RU486: dose-response effect". Fertil. Steril., 1995, 64, 187.
19. Eisinger S.H., Meldrum S., Fiscella K., Le Roux H.D., Guzick D.S.: "Low-dose mifepristone for uterine leiomyomata". Obstet. Gynecol., 2003, 101, 243.
20. Chwalisz K., Parker R.L., Williamson S., Larsen L., McCrary K., Elger W.: "Treatment of uterine leiomyomas with the novel selective progesterone receptor modulator (SPRM) J867". J. Soc. Gynecol. Investig., 2003, 10 (suppl.), 301A.
21. DeManno D., Elger W., Garg R., Lee R., Schneider B., Hess-Stumpp H. et al.: "Asoprisnil (J867): a selective progesterone receptor modulator for gynecological therapy". Steroids, 2003, 68, 1019.